PHATHOM PHARMACEUTICALS, INC. Total Long-Term Debt
PHATHOM PHARMACEUTICALS, INC. (PHAT) had Total Long-Term Debt of $164.59 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities
us-gaap:LongTermDebt · last filed 2026-07-30
- 2026-06-30: Long-term Debt $164.59M.
- 2026-03-31: Long-term Debt $163.68M.
- 2025-12-31: Long-term Debt $209.09M.
- 2025-09-30: Long-term Debt $207.09M.
| Period end | Long-term Debt |
|---|---|
| 2026-06-30 | $164.59M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $163.68M 10-Q · filed 2026-04-30 |
| 2025-12-31 | $209.09M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $207.09M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $205.14M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $203.25M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $201.41M 10-K · filed 2026-02-26 |
| 2024-09-30 | $175.73M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $174.42M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $149.02M 10-Q/A · filed 2024-06-14 |
| 2023-12-31 | $137.84M 10-K · filed 2025-03-06 |
| 2023-09-30 | $99.26M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $97.81M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $96.64M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $95.26M 10-K/A · filed 2024-06-14 |
| 2022-09-30 | $93.88M 10-Q/A · filed 2022-11-09 |
| 2022-06-30 | $92.43M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $91.04M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $89.67M 10-K · filed 2022-03-01 |
| 2021-09-30 | $88.31M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $47.69M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $47.35M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $46.99M 10-K · filed 2021-03-30 |
| 2020-09-30 | $46.62M 10-Q · filed 2020-11-10 |
| 2020-06-30 | $46.26M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $45.91M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $22.78M 10-Q · filed 2020-05-12 |
| 2019-09-30 | $22.61M 10-Q · filed 2019-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |